Long-term effects of inhaled budesonide on screening-detected lung nodules.

ABSTRACT:

Background

A previously carried out randomized phase IIb, placebo-controlled trial of 1 year of inhaled budesonide, which was nested in a lung cancer screening study, showed that non-solid and partially solid lung nodules detected by low-dose computed tomography (LDCT), and not immediately suspicious for lung cancer, tended to regress. Because some of these nodules may be slow-growing adenocarcinoma precursors, we evaluated long-term outcomes (after stopping the 1-year intervention) by annual LDCT.

Patients and methods

We analyzed the evolution of target and non-target trial nodules detected by LDCT in the budesonide and placebo arms up to 5 years after randomization. The numbers and characteristics of lung cancers diagnosed during follow-up were also analyzed.

Results

SUBMITTER: Veronesi G 

PROVIDER: S-EPMC4405280 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature